The highly metastatic ESb tumor is totally resistant to murine interferon-␣/␤ (IFN-␣/␤) therapy, regardless of the number of cells injected or the route of inoculation. In contrast, as we show herein, mouse IFN-␣ 1 -transduced ESb tumor cells were inhibited markedly when injected subcutaneously into immunocompetent mice. IFN-producing ESb tumor rejection was mediated by the immune system, because these tumor cells grew normally in immunosuppressed mice. Tumor regression was accompanied by extensive necrosis and cellular infiltrates in the tumor area. These results further support the use of IFN-␣ in cytokine gene therapy of cancer and suggest the advantage of using gene transfer rather than cytokine administration to enhance an antitumor immune response.
C ytokine gene transfer into tumor cells is regarded as a useful approach for the treatment of some human malignancies, and several clinical trials with genetically modified tumor cells producing different cytokines are in progress (reviewed in Ref. 1) . These studies were initially prompted by the observation that the production of constant amounts of various cytokines by transduced tumor cells at the site of tumor growth could elicit an effective antitumor response, often leading to the development of long-lasting tumor-specific immunity. The principal advantage of cytokine gene transfer into tumor cells versus systemic cytokine administration is the possibility of inducing protective responses without eliciting the adverse side effects associated with the administration of high doses of cytokines. Another possible advantage would be that the constitutive production of a given cytokine with tumor cells might induce host-mediated effects that are qualitatively or quantitatively different from those induced by cytokine administration.
We have reported previously that genetic transfer of the murine IFN-␣ 1 gene into different mouse metastatic tumor cells resulted in host-mediated tumor rejection and in the generation of long-lasting tumor-specific immune memory. [2] [3] [4] [5] All of the tumors used in our previous studies [2] [3] [4] [5] were responsive to exogenous interferon-␣/␤ (IFN-␣/␤) therapy. One of these, (3Cl-8 Friend leukemia cells (FLCs)), although totally resistant in vitro to IFN-␣/␤, 6 was highly sensitive in vivo to the antitumor activity of IFN-␣/␤. Metastatic development was inhibited, and mouse survival time was increased markedly. [7] [8] [9] In this study, we have transduced the highly metastatic lymphoma ESb 10 with the mouse IFN-␣ 1 gene. This tumor is also totally resistant to mouse IFN-␣/␤ in vitro. In contrast with 3Cl-8 FLCs, however, IFN-␣/␤ administration was totally ineffective in inhibiting metastases and in increasing mouse survival time. The results presented herein show that when these ESb cells, producing IFN-␣ 1 constitutively, were injected subcutaneously (s.c.) into the immunocompetent syngeneic mouse, they were often rejected, and 30 -60% of the mice survived. These findings emphasize that the genetic transfer of a cytokine into tumor cells may affect the reaction of the host to the tumor in a fashion not observed after exogenous cytokine therapy.
MATERIALS AND METHODS

Mice
Male DBA/2 and nude Swiss mice, 6 -7 weeks old, were obtained from Charles River Breeding Laboratories (Italia Calco, Italy). Splenectomized, irradiated, and anti-asialo (SIA) GM 1 -treated nude mice were prepared as described elsewhere.
Cell lines
ESb 289 is a spontaneous metastatic variant of the tumor cell line Eb, which is a subline of the methylcholanthrene-induced lymphoma L5178/YE. 10 ESb lymphoma cells were obtained from V. Schirrmacher (Deutsches Krebsforschungszentrum Heidelberg, Germany) and were passaged by intraperitoneal injection into DBA/2 mice. ESb cells were cultivated in RPMI 1640 supplemented with 10% fetal calf serum (FCS), 100 M 2-mercaptoethanol, 20 M N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid, 1% nonessential amino acids, and 1 mM sodium pyruvate. The phenotype of in vitro resistance of ESb cells to the antiproliferative effects of mouse IFN-␣/␤ was confirmed before transduction by cultivating in vivo passaged cells in the presence of IFN-␣/␤ as described elsewhere. 7 The transduced cell lines were cultivated in the same medium containing 1 mg/mL of G418 (calculated to give 100% antibiotic activity; Geneticin; Life Technologies, Grand Island, NY).
3Cl-8, an IFN-␣/␤-resistant clone of FLCs (originally obtained from E. Affabris, Università di Roma 3 Rome, Italy), 6 was cultivated in RPMI 1640 supplemented with 10% FCS.
L929 and NIH 3T3 cells (American Type Culture Collection, Manassas, Va) were cultivated in Dulbecco's modified Eagle's medium supplemented with 10% FCS.
The GPϩE-86 ecotropic 12 and GPϩenvAm12 amphotropic 13 packaging cell lines were cultivated in medium containing hypoxanthine (15 g/mL), xanthine (250 g/mL), and mycophenolic acid (25 g/mL) as described previously.
13
GPϩenvAm12 cells cultivated in the presence of 100 international units/mL of mouse IFN-␣/␤ for several passages were used for the production of the LMuIFN-␣ 1 SN retroviral vector. These GPϩenvAm12 cells exhibited a phenotype of resistance to the antiviral activity of IFN-␣/␤, as assessed by titrating the viral yield after infection with vesicular stomatitis virus. 14 
Retroviral vector production and transduction of ESb tumor cells
The LXSN retroviral vector 15 16 tailored with BamHI linkers, into the unique BamHI site of the LXSN retroviral vector, containing the neomycin resistance gene under the control of the simian virus 40 promoter. In the resulting construct, the IFN complementary DNA is under the transcriptional control of the 5Ј retroviral long terminal repeat. Both LXSN and LMuIFN-␣ 1 SN retroviral vectors were transfected in their plasmidic form into cocultures of GPϩE-86 GPϩenvAm12 packaging cells (1:1 ratio) by standard calcium-phosphate DNA precipitation procedure. Supernatants collected 7 days and thereafter following transfection were assayed for IFN and for recombinant retrovirus (assayed by infecting IFN-␣/␤-resistant 3Cl-8 cells with dilutions of the same supernatants in the presence of 4 g/mL of polybrene and by determining the number of G418-resistant clones following end-limiting dilution cloning). The supernatants exhibiting the highest titers of recombinant retrovirus and expression of IFN were then used for the transduction of ESb cells. Briefly, 5 ϫ 10 5 exponentially growing ESb cells were centrifuged and resuspended in 1 mL of retrovirus-containing supernatant in the presence of 4 g/mL of polybrene. After a 2-hour incubation at 37°C, the cultures were diluted to 5 mL with medium and incubated overnight. The following day, the cultures were subjected to a second round of infection; after 48 hours, they were placed in G418-containing selection medium. Individual G418-resistant ESb clones were isolated by end-limiting dilution cloning.
IFN titration
IFN was titrated on L929 cells as described previously. 14 
Flow cytometric analysis
The expression of specific membrane markers on the cell membrane of parental or transduced ESb cells was evaluated by immunofluorescence. Cells (1 ϫ 10 6 ) were harvested, washed in phosphate-buffered saline (PBS), and incubated for 30 minutes at 4°C in 50 L of PBS containing the appropriate antibody (Ab). When Abs not conjugated with fluorochrome were used, a second incubation for 30 minutes at 4°C in 50 L of PBS containing the appropriate fluorochrome-conjugated Ab was performed after washing the cells in PBS/2% FCS. Following incubation with fluorochrome-conjugated Abs, the cells were washed with PBS/2% FCS, diluted in 500 L of PBS, and analyzed with a FACSort fluorescence-activated cell sorter (FACS) cytometer (Becton Dickinson, San Jose, Calif). Stained cells were analyzed using Lysis II software (Becton Dickinson). The relative fluorescence intensity per cell was evaluated from samples of 5000 cells.
The Abs against mouse cell surface molecules were: fluores-
, rat anti-mouse CD80 (B7-1), and rat anti-mouse CD86 (B7-2) (all from PharMingen, San Diego, Calif); PE-conjugated anti-mouse CD8 and PE-conjugated anti-mouse CD45R (BB220) (both from Life Technologies, Bethesda, Md). Fluorescein isothiocyanate-conjugated goat antirat immunoglobulin G (Cappel, West Chester, Penn) was used to stain CD80 and B7-2 antigens (Ags).
Histological analysis
For histological evaluation, tissue samples were fixed in 10% neutral buffered formalin, embedded in paraffin, sectioned at 4 m, and stained with hematoxylin and eosin (H&E).
Statistical analysis
Data were analyzed by the Student t test.
RESULTS
Repeated administration of IFN-␣/␤ does not increase survival time in mice transplanted with metastatic ESb lymphoma
Previous studies had shown that IFN-␣/␤ was ineffective in increasing the survival time of DBA/2 mice transplanted with the ESb tumor; 17, 18 however, IFN-␣/␤ proved very effective in mice injected with other tumors (reviewed in Ref. 19 ). In the experiment illustrated in Figure 1 , we have determined whether repeated injections of high doses of IFN-␣/␤ soon after the s.c. transplantation of ESb could exhibit any therapeutic effect compared with control-treated mice. Daily treatment with 2 ϫ 10 5 U of IFN at the site of tumor injection (initiated immediately after the inoculation of cells) did inhibit the growth of the primary tumor in some mice (data not shown), but did not increase the survival time (Fig 1) , whereas a similar treatment induced a very marked antitumor response in DBA/2 mice transplanted with metastatic FLCs. 7, 8 These results indicate that IFN-␣/␤ is totally ineffective in inhibiting the development of ESb metastases even when high doses of the cytokine are given repeatedly at the tumor site.
Isolation and characterization of ESb tumor cells secreting IFN-␣ after transduction with a recombinant retrovirus
ESb tumor cells were transduced with recombinant retroviruses obtained from the retroviral vectors LMuIFN-␣ 1 SN and LXSN (Fig 2) . The majority of the clones obtained following selection in G418-containing medium secreted low to intermediate amounts of biologically active IFN-␣; those clones chosen for additional characterization are indicated in Table 1 . E-TC-7 represents a clone transduced with the LXSN vector and used as a control for possible effects of the vector sequences. The proliferation rate in vitro of the IFNproducing ESb cells did not differ substantially from that of parental ESb tumor cells or control E-TC-7 cells (data not shown). FACS analysis revealed an increase in the expression of the H-2D d Ags and, to a lesser extent, of H-2K
d Ags at the cell surface of all of the IFN-producing ESb cell clones with respect to ESb parental tumor cells (Fig 3) . The expression levels of other Ags (i.e., CD80, CD86, CD8, and CD45R) did not change (data not shown). Table 2 illustrates the results of two representative experiments in which 10 6 or 10 5 parental ESb, E-TC-7 control, or IFN-␣-producing ESb tumor cells were injected s.c. into syngeneic immunocompetent DBA/2 mice. The injection of ESb parental or E-TC-7 control tumor cells resulted in the formation of rapidly growing s.c. tumors and liver metastases and in the death of all injected mice. In contrast, IFN-producing ESb cell clones were rejected in a significant proportion (30 -60%) of injected mice, depending upon the clone and the cell dose. Initial growth of the s.c. tumor followed by complete rejection was observed in all surviving mice. Other mice injected with IFN-producing ESb cells died with liver metastases, even though the primary tumor had regressed completely in some of these mice. However, an i.v. injection of varying numbers of IFN-producing ESb tumor cells resulted in the death of all injected mice due to the visceral metastases, as was seen for mice injected i.v. with ESb parental or E-TC-7 control tumor cells (data not shown).
Growth characteristics of IFN-producing ESb tumor cells in DBA/2 mice
Histology of tumor rejection in mice injected s.c. with ESb tumor cells secreting IFN-␣
The histology of the s.c. tumor area in mice injected with IFN-␣-producing ESb cells showed extensive areas of tumor necrosis ( Fig 4B) ; such areas were not observed in the s.c. tumors formed by parental ESb tumor cells ( Fig  4A) . Analysis of the host cell infiltrates at various timepoints showed that, at 1 week after s.c. injection of the IFN-producing ESb cells, the vessels underlying the tumors contained many granulocytes, lymphocytes, and monocytes (Fig 5A) , which were not observed in the tumor area of mice injected with either the parental ESb or control E-TC-7 tumor cells (data not shown). When the IFN-producing ESb tumors were mostly necrotic (2-3 weeks after injection), host cellular infiltrates were present both at the tumor-to-necrosis border (Fig 5B) and at the periphery of the tumor, encased in a net of fibroblasts (Fig 5C) .
Importance of host-mediated mechanisms in tumor rejection in mice transplanted with IFN-␣-producing ESb cells
The injection of two different IFN-␣-producing ESb cell clones in SIA nude mice led to rapid tumor growth and to the death of all mice; the time course was comparable with that of mice injected with ESb parental tumor cells (Fig 6A) . In contrast, injection of the same two IFNtransduced ESb cell clones into immunocompetent DBA/2 mice resulted in complete tumor rejection in 50 -60% of the injected animals ( Fig 6B) . These results indicate that the rejection of IFN-␣-producing ESb tumor cells was not due to a loss of the in vivo growth capacity of these cells but rather to an IFN-induced host-mediated response in the immunocompetent mouse.
DISCUSSION
Although treatment with large amounts of IFN-␣/␤ has proven effective in inhibiting the growth of most transplantable tumors in mice, 19 it has consistently proven ineffective in increasing survival time in mice injected with the ESb lymphoma, even when few tumor cells were injected (Ref. 17 and Fig 1) . In contrast, the results presented herein show that the constitutive expression of IFN-␣ 1 by genetically modified ESb tumor cells (resistant in vitro to IFN-␣/␤) results in rejection of the s.c. implanted ESb tumor, and 27-60% of transduced tumor-injected mice survived (Table 2) . These results were observed with each of the six IFN-␣ 1 -producing ESb clones tested and were not due to possible autocrine antiproliferative effects of the IFN-␣ 1 secreted by the transduced ESb cells, as the proliferation rate of IFN-producing ESb cells in vitro did not differ from that of parental ESb cells or control E-TC-7 cells (data not shown).
Our findings point to the existence of differences between administration of a cytokine and its constitutive expression by tumor cells, in terms of induction of a protective response. In fact, although possible effects of IFN on the expression of genes that can directly affect the metastatic phenotype of ESb cells 20, 21 cannot be ruled out, our observation that IFN-producing ESb cells were fully tumorigenic in totally immunosuppressed mice (Fig 6) demonstrates the importance of hostmediated mechanisms in the rejection of these tumor cells. Our finding that 50 -60% of the mice that had rejected a previous s.c. injection of IFN-producing ESb cells were resistant to a contralateral s.c. challenge with a lethal dose of parental ESb tumor cells after the initial inoculum at 4 months (data not shown) indicates that the IFN-producing ESb cells are capable of eliciting a long-lasting systemic antitumor immune response that is 2) tumor cells. At autopsy, liver and spleen metastases were detected in all dead mice. Tumor-free mice were sacrificed at day 60 in expt. 1 and at day 120 in expt. 2. At autopsy, no visceral metastases were observed in these animals.
† P Ͻ .001 vs. ESb-injected mice; ‡ P Ͻ .05 vs. ESb-injected mice; § NS, not significant. effective in counteracting the metastatic spread and growth of the parental tumor.
FACS analysis showed an increase in the expression of H-2D d and, to a lesser extent, of H-2K d Ags at the cell surface of all IFN-producing ESb cell clones (Fig 3) . Even though changes in the expression of other ESb cell surface Ags 22 were not detected in IFN-␣-producing ESb cells, IFN-␣ constitutive secretion may render the transduced ESb cells a better target for immune recognition by modifying the expression of ESb tumor-associated transplantation Ags, which have been shown to induce weak protective immunity and activate specific cytotoxic T lymphocytes. 23 Our previous results had emphasized the importance of the host immune response in mice injected i.v. with ESb cells. Thus, IFN-␣/␤ therapy was effective only when tumor-injected mice also received immune syngeneic CD8
ϩ T cells by adoptive transfer and the combined therapy of immune cells and IFN-␣/␤ resulted in long-term immunity to this tumor. 17 Further experiments showed that host CD4
ϩ T cells were also essential. 24 The importance of IFN-␣/␤ in the activation of a protective cell-mediated immune response against the ESb tumor has been demonstrated in studies by Schirrmacher and colleagues. [25] [26] [27] These investigators showed that the therapeutic efficacy of virus-modified tumor vaccines, consisting of ESb cells infected with Newcastle disease virus (a potent inducer of IFN-␣/␤), was due to their ability to activate tumor-associated transplantation Ag-specific cytotoxic T-lymphocyte precursors, 25 required stimulation with the specific Ag/ tumor cell plus helper factors (IL-2 or IFN-␣/␤), 26 and was abrogated by Abs to IFN-␣/␤. 27 Moreover, the presence of low concentrations of IFN-␣/␤ in mixed lymphocyte cultures selectively increased the specific activity of Ag-driven T cells. 27 In the immunization studies, it was observed that the ear pinna appeared to be a privileged site for induction of the host antitumor immune response, perhaps due to the concentration of Ag-presenting cells (i.e., Langerhans cells). 28 Our observations that IFN-producing ESb tumor cells grew poorly following s.c. inoculation, whereas the same cells were as tumorigenic as the parental ESb cells following i.v. injection, suggest that the secretion of IFN-␣, associated with tumor Ag at the s.c. site of tumor growth, acts as a strong signal for the recruitment and activation of Ag-presenting cells, such as macrophages, which may then stimulate a T-cell-mediated antitumor response. This hypothesis is supported by histological analysis of the tumor area in mice injected with IFN-producing ESb cells, which showed the presence of a prominent inflammatory infiltrate and extensive necrosis. Although a similar histology may be observed in mice injected peritumorally with large amounts of IFN-␣/␤, a durable antitumor response was not observed. This discrepancy may be due to possible antigenic differences of the transduced ESb cells or to the rapid catabolism of the cytokine which, when administered, cannot reach or maintain optimal local levels. In this regard, it is of interest that even ESb cell clones secreting low amounts of IFN-␣ can be rejected (Table 2) . One possible explanation is that the in vivo proliferation of the transduced tumor cells during the initial phases of tumor growth permits a sustained production of the IFN-␣. Moreover, the concentrations of both IFN-␣ and tumor Ags would be greatest at the site of tumor growth, due to the close proximity of the proliferating tumor cells to the secreted IFN, favoring both activation of host effector cells and their recognition of tumor cells.
In addition to promoting the initiation of an immune response, the IFN-␣ produced continuously during in vivo proliferation of the transduced ESb tumor cells may also favor the development of an antitumor immunological memory, via the expansion of tumor-specific T lymphocytes. It was found recently that type I IFN prolongs the proliferation and survival in vivo of longlived Ag-specific memory CD8 ϩ T cells. 29 Tumor necrosis factor (TNF) is the only other cytokine that, to our knowledge, has been transduced into ESb tumor cells. 30 Genetic transfer of this cytokine resulted in the promotion of metastasis formation following s.c. injection of modified ESb cells, whereas it caused a suppression of tumor growth of the nonmetastatic Eb cells. 30 In this study, the failure of TNF to suppress ESb metastasis correlated with the inability of TNF-secreting ESb cells to induce an efficient inflammatory response, as revealed by immunohistological analysis. 30 Our previous results had indicated that IFN-␣ may be superior to other cytokines in its capacity to stimulate an antitumor response. [2] [3] [4] [5] In conclusion, our study represents the first example of the advantage of cytokine gene transfer over administration of the cytokine in terms of the induction of a protective antitumor immune response and increased survival time. These results provide further support for the use of IFN-␣ in the development of tumor vaccines.
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